Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Find a Doctor

Toni Choueiri, MD

Medical Oncology

 Make an Appointment
Watch Video

Toni Choueiri, MD americas top doctors

Physician

  • Director, Lank Center for Genitourinary Oncology
  • Medical Director, International Strategic Initiatives
  • Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School

Centers/Programs

Clinical Interests

  • Genitourinary tumors
  • Renal cell carcinoma (kidney)

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-632-5456
  • Fax617-632-2165
Make an Appointment

Bio

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018). He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA. Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.

Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of New England Journal of Medicine (NEJM) articles on which he was either first or senior author, Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, and Pembrolizumab+Lenvatinib, as well as adjuvant pembrolizumab. His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He has also contributed to our understanding of the underlying biology and rationale for therapies in rare histological variants of RCC such as papillary, translocation, and sarcomatoid RCC.

Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), and industry partners. His work has been published in journals such as the NEJM, Nature, Nature Medicine, Science, Cancer Cell, Journal of American Medical Association (JAMA), JAMA Oncology, The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He lectures frequently throughout the United States and around the world. He has over 675 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.

Board Certification:

  • Internal Medicine, 2004
  • Medical Oncology, 2007

Fellowship:

  • Cleveland Clinic Foundation, Hematology/Medical Oncology

Residency:

  • Cleveland Clinic Foundation, Internal Medicine

Medical School:

  • Saint Joseph University Faculte of Medicine

Research

Novel therapies in genitourinary cancers with a focus on kidney cancers

Dr. Choueiri is interested in the clinical and molecular predictors of outcome to therapies in renal cancers.

Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. In: Curr Opin Investig Drugs. Thompson Scientific; 2008. p. 658-71.

2008

Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009; 10: 967-74.

2009

Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Cane Netw. 2009; 7: 659-65.

2009

Lotan, Y, Choueiri, TK. Clinical presentations, diagnosis, and staging of bladder cancer. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2010.

2010

Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, and Escudier B. Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. J Clin Oncol. 2008;26(1):127-131.

Escudier B, Choueiri TK, Oudard S, Szczylik C, Ngrier S, Ravaud A, Chevreau C, Venner P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM. Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. J Urol. 2007: pp. 1901-1905.

Choueiri TK,Tamaskar I, Sercia L, Rini B, Bukowski R, Zhou M. Differential expression of caveolin-1 in renal neoplasms. Cancer. 2007;110(4):776-82.

Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110(3):543-50

Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007;18(2):249-55.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006;107(11):2609-16.

Abou-Jawde RM, Baz R, Walker E, Choueiri TK, Karam MA, Reed J, Faiman B, Hussein M. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica. 2006;9 (10):1410-3.

Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30(9):1097-104.

Choueiri TK, Mekhail T, Hutson TE, Ganapathi R, Kelly GE, Bukowski RM. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol. 2006;17(5):860-5.

Support My Research

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top